Key regions: Germany, United States, India, Japan, United Kingdom
The demand for Anti-Rheumatic Drugs in Romania is on the rise due to various factors.
Customer preferences: Patients in Romania are increasingly seeking treatment for rheumatic diseases, which is driving the demand for Anti-Rheumatic Drugs. This is due to the aging population and the rising prevalence of rheumatic diseases in the country. Patients are also becoming more aware of the different treatment options available to them, and are willing to try new drugs to manage their condition.
Trends in the market: The Anti-Rheumatic Drugs market in Romania is expected to grow in the coming years due to the increasing prevalence of rheumatic diseases in the country. The market is also being driven by the introduction of new drugs and therapies, which are more effective in managing the symptoms of rheumatic diseases. The market is also expected to benefit from the increasing awareness among patients and healthcare professionals about the importance of early diagnosis and treatment of rheumatic diseases.
Local special circumstances: The Romanian government has been taking steps to improve access to healthcare services in the country, which is expected to benefit the Anti-Rheumatic Drugs market. The government has been increasing healthcare spending in recent years, and has also been working to improve the quality of healthcare services in the country. This is expected to lead to an increase in the number of patients seeking treatment for rheumatic diseases, which will drive the demand for Anti-Rheumatic Drugs.
Underlying macroeconomic factors: The Romanian economy has been growing in recent years, which is expected to benefit the Anti-Rheumatic Drugs market. The growing economy has led to an increase in disposable income among the population, which means that patients are more willing to spend money on healthcare services. The growing economy has also led to an increase in healthcare spending by the government, which is expected to benefit the Anti-Rheumatic Drugs market. Additionally, the country’s membership in the European Union has led to an increase in foreign investment in the healthcare sector, which is expected to further drive the growth of the Anti-Rheumatic Drugs market in Romania.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
